Release No 10/2010 Affitech New Shares Registered Trans Nova Investments Limited has paid the subscription price of DKK 156,112,206.00 The share capital increase has been registered with the Commerce and Companies Agency 260,187,010 new shares each of nominal value DKK 0.50 have been issued to Trans Nova Investments Limited and Trans Nova now owns 53.35% of the new share capital The new share capital of the Company is now DKK 243,860,769,50 and comprises 487,721,539 voting rights Copenhagen and Oslo, April 23, 2010 Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today announced that the subscription by Trans Nova Investments Limited of 260,187,010 new shares each of nominal value DKK 0.50 in return for DKK 156,112,206.00 has been completed and the subscription price received by the Company. As a consequence, Trans Nova Investments now owns 53.35% of the share capital of the Company and controls 260,187,010 voting rights. -------------------------------------------------------------------------------- | For more information please contact: | -------------------------------------------------------------------------------- | | | Affitech A/S: | | | | Dr Robert Burns, Chief Executive Officer, | | Tel # +45 50 99 76 42 | | Randi Krogsgaard, Corporate Communications | | Tel # +45 23 20 10 01 | -------------------------------------------------------------------------------- About Affitech Affitech AS is a publicly traded (NASDAQ OMX Copenhagen exchange) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.